NO996097L - Lag-3 spleis varianter - Google Patents

Lag-3 spleis varianter

Info

Publication number
NO996097L
NO996097L NO19996097A NO996097A NO996097L NO 996097 L NO996097 L NO 996097L NO 19996097 A NO19996097 A NO 19996097A NO 996097 A NO996097 A NO 996097A NO 996097 L NO996097 L NO 996097L
Authority
NO
Norway
Prior art keywords
nucleotidic
seq
code
sequences
layer
Prior art date
Application number
NO19996097A
Other languages
English (en)
Other versions
NO996097D0 (no
Inventor
Frederic Triebel
Renato Mastrangeli
Sergio Romagnani
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave, Applied Research Systems filed Critical Inst Nat Sante Rech Med
Publication of NO996097D0 publication Critical patent/NO996097D0/no
Publication of NO996097L publication Critical patent/NO996097L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
NO19996097A 1997-06-18 1999-12-09 Lag-3 spleis varianter NO996097L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401404A EP0900841A1 (en) 1997-06-18 1997-06-18 LAG-3 splice variants
PCT/EP1998/003307 WO1998058059A1 (en) 1997-06-18 1998-06-03 Lag-3 splice variants

Publications (2)

Publication Number Publication Date
NO996097D0 NO996097D0 (no) 1999-12-09
NO996097L true NO996097L (no) 2000-02-17

Family

ID=8229784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19996097A NO996097L (no) 1997-06-18 1999-12-09 Lag-3 spleis varianter

Country Status (18)

Country Link
EP (2) EP0900841A1 (no)
JP (1) JP2002505582A (no)
KR (1) KR100552526B1 (no)
CN (1) CN1181201C (no)
AT (1) ATE274057T1 (no)
AU (1) AU740147B2 (no)
BR (1) BR9810925A (no)
CA (1) CA2293735A1 (no)
DE (1) DE69825741T2 (no)
DK (1) DK0977856T3 (no)
EA (1) EA003086B1 (no)
EE (1) EE04378B1 (no)
ES (1) ES2227862T3 (no)
HK (1) HK1027377A1 (no)
IL (2) IL133544A0 (no)
NO (1) NO996097L (no)
PT (1) PT977856E (no)
WO (1) WO1998058059A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100359A1 (en) * 2000-10-04 2003-05-29 Loose Timothy C. Audio network for gaming machines
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7867085B2 (en) 2003-01-16 2011-01-11 Wms Gaming Inc. Gaming machine environment having controlled audio and visual media presentation
US7364508B2 (en) 2003-01-16 2008-04-29 Wms Gaming, Inc. Gaming machine environment having controlled audio and visual media presentation
US7367886B2 (en) 2003-01-16 2008-05-06 Wms Gaming Inc. Gaming system with surround sound
US8313374B2 (en) 2003-02-14 2012-11-20 Wms Gaming Inc. Gaming machine having improved audio control architecture
WO2004078928A2 (en) * 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
WO2008063391A2 (en) 2006-11-10 2008-05-29 Wms Gaming Inc. Wagering games using multi-level gaming structure
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS58705B1 (sr) 2013-09-20 2019-06-28 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
US9412222B2 (en) 2013-09-20 2016-08-09 Igt Coordinated gaming machine attract via gaming machine cameras
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
GEP20227438B (en) 2015-07-30 2022-11-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
AU2016371639A1 (en) 2015-12-16 2018-06-28 Merck Sharp & Dohme Llc Anti-LAG3 antibodies and antigen-binding fragments
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
EP3631454B1 (en) 2017-05-30 2023-09-13 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
KR20220007593A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134874B2 (ja) * 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5955300A (en) * 1994-05-06 1999-09-21 Institut Gustave Roussy Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies

Also Published As

Publication number Publication date
EA003086B1 (ru) 2002-12-26
EP0977856B1 (en) 2004-08-18
DK0977856T3 (da) 2004-12-20
IL133544A0 (en) 2001-04-30
AU740147B2 (en) 2001-11-01
EE04378B1 (xx) 2004-10-15
KR20010013539A (ko) 2001-02-26
JP2002505582A (ja) 2002-02-19
EE9900581A (xx) 2000-08-15
NO996097D0 (no) 1999-12-09
WO1998058059A1 (en) 1998-12-23
EA200000038A1 (ru) 2000-06-26
DE69825741D1 (de) 2004-09-23
IL133544A (en) 2006-12-31
BR9810925A (pt) 2000-08-15
ATE274057T1 (de) 2004-09-15
ES2227862T3 (es) 2005-04-01
CN1260833A (zh) 2000-07-19
DE69825741T2 (de) 2005-09-01
AU8435598A (en) 1999-01-04
HK1027377A1 (en) 2001-01-12
KR100552526B1 (ko) 2006-02-14
PT977856E (pt) 2005-01-31
EP0977856A1 (en) 2000-02-09
CA2293735A1 (en) 1998-12-23
CN1181201C (zh) 2004-12-22
EP0900841A1 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
NO996097D0 (no) Lag-3 spleis varianter
AU7550098A (en) System for expressing hyperthermostable protein
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69636495D1 (de) Multi-tumor abweichende wachstumsgene
ATE399858T1 (de) Blütenorgan-spezifische promotersequenzen
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
ATE205257T1 (de) Gene kodierend für ultrathermostabile proteasen
DE60015042D1 (de) Nukleotidsequenzen, welche für das dapF-Gen kodieren
DE59109072D1 (de) Klonierung der N-Methylhydantoinase
HUP0001969A2 (hu) Az NNT-1 neurotróf faktor
ATE121456T1 (de) Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus.
AU7655994A (en) Cloning of a member of the serine-threonine-kinase family
SE9801098D0 (sv) Receptors
DE69831584D1 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
WO2000017232A3 (de) Regulatorisches protein aus humanen keratinozyten
ATE180015T1 (de) N-carbamoylsarcosin-amidohydrolase, kloniert
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DE60021707D1 (de) Beta-primeverosidase gen
WO1999060117A3 (fr) Polypeptide prax-1
TH14326A (th) โปรตีเอสและสารประกอบดีเอนเอที่เกี่ยวข้อง

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS